Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCENT 2 maintenance study of mirikizumab in ulcerative colitis
2017-003238-96Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Mirikizumab maintenance with Placebo maintenance (2 arms). Primary endpoint: Clinical remission at Week 40. Started May 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-003238-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003238-96.